1 year ago

2015 Scientific Report

  • Text
  • Report
  • Institute
  • Clinical
  • Biology
  • Tumor
  • Signaling
  • Molecular
  • Vari
  • Laboratory

Van Andel Research

Van Andel Research Institute | Scientific Report 2015 Recent Publications Staal, Ben, Bart O. Williams, Frank Beier, George F. Vande Woude, and Yu-Wen Zhang. 2014. Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chrondrocyte proliferation. Proceedings of the National Academy of Sciences U.S.A. 111(7): 2590–2595. Graveel, Carrie R., David Tolbert, and George F. Vande Woude. 2013. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harbor Perspectives in Biology 5(7): a009209. Merchant, Mark, Xiaolei Ma, Henry R. Maun, Zhong Zheng, Jing Peng, Mally Romero, Arthur Huang, Nai-ying Yang, Merry Nishimura, et al. 2013. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences U.S.A. 110(32): E2987–E2996. Paulson, Amanda K., Erik S. Linklater, Bree D. Berghuis, Colleen A. App, Leon D. Oostendorp, Jayne E. Paulson, Jane E. Pettinga, Marianne K. Melnik, George F. Vande Woude, et al. 2013. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Molecular Cancer Research 11(9): 1112–1121. Xie, Qian, Yanli Su, Karl Dykema, Jennifer Johnson, Julie Koeman, Valeria De Giorgi, Alan Huang, Robert Schlegel, Curt Essenburg, et al. 2013. Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. Genes & Cancer 4(7-8): 247–260. Zhang, Yu-Wen, Ben Staal, Curt Essenburg, Steven Lewis, Dafna Kaufman, and George F. Vande Woude. 2013. Strengthening context-dependent anticancer effects on non–small cell lung carcinoma by inhibition of both MET and EGFR. Molecular Cancer Therapeutics 12(8): 1429–1441. Zhang, Yu-Wen, and George F. Vande Woude. 2013. MIG-6 and SPRY2 in the regulation of receptor tyrosine kinase signaling: balancing act via negative feedback loops. In Future Aspects of Tumor Suppressor Genes, Yue Chang, ed. Rijeka, Croatia: InTech, pp. 199–221. 34

Bart O. Williams, Ph.D. Laboratory of Cell Signaling and Carcinogenesis Dr. Williams received his Ph.D. in biology from Massachusetts Institute of Technology in 1996 where he trained with Tyler Jacks. For three years, he was a postdoctoral fellow at the National Institutes of Health in the laboratory of Harold Varmus, former Director of NIH. Dr. Williams joined VARI as a Scientific Investigator in July 1999. He is now a Professor and the Director of the Center for Cancer and Cell Biology. From left: Droscha, Lewis, Maupin, Ethen, Diegel, Nguyen, Valkenburg, VanHouten, McDonald, Williams Staff Students Adjunct Faculty Visiting Scientist Cassandra Diegel, B.S. Diana Lewis, A.S. Mitch McDonald, B.S. Casey Droscha, B.S. Nicole Ethen Kevin Maupin, B.A., B.S. Rebecca Nguyen Ken Valkenburg, B.S. Clifford Jones, M.D. Debra Sietsema, Ph.D., RN Chad VanHouten, M.S. 35

Publications by Year